Key Takeaways
Because the full Street average for Elevance Health sits only slightly above the current share price, the $475 figure used here is the arithmetic mean of the verified analyst targets that remain above the market price. Twelve such targets, spanning roughly $450 to $498, average to about $472—rounded to a clean $475. For context, the overall mean of all valid targets is materially lower, around $441 to $452 depending on the source, while the full range runs from about $360 to $498.
Views are broadly constructive but not uniform. Recent revisions have tilted higher: Deutsche Bank lifted the stock to Buy with a $498 target, Bank of America Securities raised its target to $480, Bernstein moved to $488, and Barclays raised its figure to $469. Truist ($475) and Wells Fargo ($473) also sit near the central target. On the more cautious side, RBC Capital, Morgan Stanley, Baird, and Evercore ISI carry Hold-equivalent ratings with targets of roughly $360 to $424, reflecting concern about government-program margins and policy risk.
Elevance Health last closed around $428, giving the company a market capitalization of roughly $93 billion and a trailing P/E (price-to-earnings) ratio near 19. Moving to $475 implies an advance of about 11%—a modest but still meaningful move for a large-cap managed-care operator. The stock has already recovered sharply from its 52-week low near $275 and now trades just below its 52-week high of about $436.
The most direct path toward the target would involve a combination of sustained earnings growth, confirmation that government-program margins are stabilizing, and continued analyst target increases. As one of the largest U.S. health-benefits companies—the leading Blue Cross Blue Shield licensee across 14 states, serving roughly 45 million medical members—Elevance also generates steady cash flow that supports a dividend of about $6.88 per share, or a yield near 1.6%.
Several verified factors support a constructive outlook. Analysts point to margin recovery in Medicare Advantage and Medicaid after a period of elevated medical costs, along with stable employer-sponsored membership. Recent earnings commentary has shown improving trends, with results beating expectations and revenue growing by double digits on a year-over-year basis. A steady stream of target increases from Barclays, Bank of America, Bernstein, Truist, and Wells Fargo suggests Street estimates are being revised upward. A rotation back into the healthcare sector and a relatively undemanding valuation versus historical levels could also provide a tailwind.
The principal obstacles are policy- and cost-driven. Changes to Medicare Advantage payment rates, Star Ratings, and Medicaid redetermination rules can compress margins and reduce membership, and Elevance has significant exposure to these government programs. A reacceleration in medical utilization or a weaker-than-expected earnings report would likely pressure the stock and trigger target cuts, as occurred in prior quarters. With shares already near their 52-week high, some of the recovery may already be reflected in the price, leaving less room for valuation expansion.
Technically, the stock sits in a well-defined uptrend after rallying from its March low near $275. The immediate hurdle is the prior 52-week high around $436, which has acted as resistance since mid-2026. A sustained move above that level would open the way toward the $450 round-number zone and then the $475 target. On the downside, the $420–$425 area and the $400 psychological level represent the first meaningful support zones.
Analyst price targets typically reflect a roughly 12-month research horizon, and the figures cited here generally follow that convention. The next major catalyst is the company's quarterly earnings report, scheduled for late October 2026, when management guidance on medical-cost trends, government-program margins, and membership will set the tone. Investors should also monitor Medicare Advantage rate announcements, Medicaid policy developments, and any further analyst revisions, all of which could shift the range of targets.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those following Elevance Health alongside a broader watchlist, the tool offers a streamlined way to track evolving momentum and risk signals in one place.
The $475 central target is an average of the analyst price targets that currently sit above Elevance Health's market price, and it implies an advance of roughly 11% from the latest close near $428. The case for the move rests on margin recovery in government programs, steady earnings growth, and a pattern of rising Street targets, while the case against it centers on Medicare Advantage and Medicaid policy risk, medical-cost uncertainty, and a stock already near its 52-week high. The wide dispersion of targets—from roughly $360 to $498—underscores genuine disagreement about the durability of the recovery. With earnings due in late October, near-term guidance and cost trends will be the clearest signals of whether the path toward $475 remains open.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ELV has been closely correlated with UNH. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ELV jumps, then UNH could also see price increases.